Journal profile · Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Pharmaceutical Science Advances
ISSN 2773-2169 · Elsevier · Netherlands
Pharmaceutical Science Advances: fully open access; APC about USD 2,000; median 102 days to acceptance (65 articles, last 24 months); 40 articles in 2025; indexed in Scopus.
Scope
Aims, scope and focus
Pharmaceutical Science Advances is published by Elsevier. By OpenAlex counts of its recent articles, its largest topics are Nanoparticle-Based Drug Delivery, Computational Drug Discovery Methods and Advanced Drug Delivery Systems, together about 32.7% of its articles. Its main subfields are Pharmaceutical Science. (generated from OpenAlex topic counts and CAS ranking data)
An Official Journal of Shandong UniversityPharmaceutical Science Advances is an open access journal dedicated to publishing rigorously peer-reviewed, high-quality research in all areas of the pharmaceutical research. Appropriate topics include, but are not limited to, pharmacology, pharmaceutics, genomics and proteomics, medicinal chemistry, natural products, pharmacognosy, drug metabolism, pharmaceutical analysis, pharmacokinetics, and clinical characteristics of important drugs. We are also interested in interdisciplinary research that connects pharmaceutical sciences to, for example, administration, management, ethics, law, economics, as well as biomedical engineering, materials science, mechanology, etc.We are committed to providing an efficient service for both authors and readers. Prompt dissemination of accepted papers to a wide readership and beyond is achieved through a programme of continuous online publication.
From the journal's Aims & Scope
Research area (LetPub): Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Editor-in-chief Jianmin YuePublisher website
Editorial board by country: 16 in mainland China (about 52%); most named Mainland China 16, United States 6, Portugal 3, United Kingdom 1, India 1 (31 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Nanoparticle-Based Drug DeliveryMaterials Science11.5%
- Computational Drug Discovery MethodsComputer Science10.9%
- Advanced Drug Delivery SystemsPharmacology, Toxicology and Pharmaceutics10.3%
- Drug Solubulity and Delivery SystemsPharmacology, Toxicology and Pharmaceutics7.9%
- Medicinal Plant ResearchAgricultural and Biological Sciences6.1%
- Cancer Immunotherapy and BiomarkersMedicine3.6%
- Advancements in Transdermal Drug DeliveryPharmacology, Toxicology and Pharmaceutics3.6%
- Bioactive natural compoundsBiochemistry, Genetics and Molecular Biology3.6%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Not covered
Not covered by this edition.
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
CiteScore quartiles (Scopus, June 2026 release)
| Subject | Quartile | Rank | Percentile |
|---|---|---|---|
| Pharmacology, Toxicology and Pharmaceutics (miscellaneous) | Q1 | 6/57 | 90th |
| Pharmaceutical Science | Q2 | 61/191 | 68th |
| Pharmacology | Q2 | 105/328 | 68th |
Scopus ranks journals by CiteScore within each subject: the 75th percentile and above is Q1, then a quartile every 25 points. A different system from the CAS zones.LetPub
Database indexing
ScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
PubMedPublisher website
Other: Crossref
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
- CiteScore 2026-06
- 5.9LetPub ·
- CiteScore (publisher)
- 5.9Publisher website ·
- SJR 2026-06
- 1.08LetPub ·
- SNIP 2026-06
- 1.92LetPub ·
- h-index
- 19OpenAlex ·
- i10-index
- 37OpenAlex ·
- 2-year mean citedness
- 6.46OpenAlex ·
- Share of gold OA articles
- 0%LetPub ·
Articles by year OpenAlex count · 136 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 48 | 48 | 715 |
| 2025 | 40 | 40 | 362 |
| 2024 | 23 | 23 | 118 |
| 2023 | 23 | 23 | 7 |
| 2022 | 2 | 2 | 0 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
102 daysMedian, submission to acceptance · P25–P75 77 days – 135 days
- Acceptance to online
- median 2 days (65 articles)
- Submission to online
- median 106 days
- Sample
- 65 articles with submission and acceptance dates (0 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 13 weeksLetPub ·
- Submission to first decision
- 2 daysPublisher website ·
- Submission to acceptance
- 105 daysPublisher website ·
- Acceptance to publication
- 2 daysPublisher website ·
- Submission to publication (journal-reported)
- about 18 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 2,000 | Yes | CC BY, CC BY-NC-ND | |
| OpenAlex | USD 2,000 / EUR 1,870 / GBP 1,600 / JPY 248,060 | — | — | |
| LetPub | USD 2,000 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare3 items from the author guidelines
- Reference style
- Numbered, in order of citation
- Suggested reviewers
- Required
- Graphical abstract
- Optional
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Publication ethics, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI in scientific writing
Generative AI use must be declared Model summary
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Author contributions
Original work not published elsewhere Model summary
For transparency, we require corresponding authors to provide co-author contributions to the manuscript using the relevant CRediT roles. The CRediT taxonomy includes 14 different roles describing each contributor's specific contribution to the scholarly output. The roles are: Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration;…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interest
Competing interest disclosure required Model summary
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors should complete the declaration of compe…
Source ↗Publisher website ·- Publication ethics
Human subjects research must comply with Declaration of Helsinki Model summary
If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans.
Source ↗Publisher website ·- License & copyright Copyright
License agreement upon acceptance Model summary
Upon acceptance of an article, authors will be asked to complete a 'License Agreement' (see more information on this). Permitted third party reuse of open access articles is determined by the author's choice of user license.Author rightsAs an author you (or your employer or institution) have certain rights to reuse your work. More information.
Source ↗Publisher website ·- Open access Open Access
Third party reuse determined by user license Model summary
Please visit our Open Access page for more information about open access publishing in this journal.
Source ↗Publisher website ·- Peer review Peer review
Single anonymized review process Model summary
This journal operates a single anonymized review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor'…
Source ↗Publisher website ·- Preprints Preprints
Preprints can be shared anywhere at any time Model summary
Please note that preprints can be shared anywhere at any time, in line with Elsevier's sharing policy. Sharing your preprints e.g. on a preprint server will not count as prior publication (see 'Multiple, redundant or concurrent publication' for more information).
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Before you submit
Five checks before submitting to Pharmaceutical Science Advances
- 1ScopeRecent output centres on Nanoparticle-Based Drug Delivery, Computational Drug Discovery Methods.Check scope
- 2Article type and formatReference style: Numbered, in order of citation; Suggested reviewers: Required; Graphical abstract: Optional.Author guidelines ↗
- 3English languagePolish grammar and academic style before you submit: it lowers the risk of rejection for language and improves your chances of acceptance.
- 4FeesUSD 2,000 (DOAJ), waivers availableFee details
- 5Expected review time102 days · Median, submission to acceptance · 65 articles, last 24 months · PubMedReview data
The checks are built from this page's data.
Profile
Publication details and official links
- Publisher
- Elsevier
- Country or region
- Netherlands
- Language
- English
- ISSN
- 2773-2169
- Society / sponsor
- Shandong University
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
FAQ
Frequently asked questions about Pharmaceutical Science Advances
How long does peer review take at Pharmaceutical Science Advances?
Based on the dates recorded on 65 articles published between November 2024 and November 2026 (the last 24 months), the median time from submission to acceptance is 102 days (interquartile range 77–135 days); authors report an average review time of about 13 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Pharmaceutical Science Advances?
According to the journal's author guidelines: Reference style: Numbered, in order of citation; Suggested reviewers: Required; Graphical abstract: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Pharmaceutical Science Advances based?
Of the 31 board members whose country the journal's board page names, 16 (about 52%) are in mainland China; the countries named most often are Mainland China (16), United States (6) and Portugal (3). Counted from the institutions listed on the board page; for reference only.
Which databases index Pharmaceutical Science Advances?
According to LetPub and DOAJ records, Pharmaceutical Science Advances is indexed in Scopus and DOAJ. The journal's website also lists PubMed; that list has not been checked against each database.
Is Pharmaceutical Science Advances open access, and what is the APC?
Pharmaceutical Science Advances is a fully open-access journal. APC about USD 2,000.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .